ORPHELIA Pharma
Children with rare diseases deserve therapeutic answers
Children with rare diseases deserve therapeutic answers
ORPHELIA Pharma, a French pharmaceutical company based in Paris and Lyon, is dedicated to developing and marketing medicines for the treatment of pediatric orphan diseases. Its mission is to provide essential products in the fields of epilepsy and pediatric oncology, with formulations tailored for the pediatric population. Established in 2007, the company already has one drug approved in the European Union and another product in late-stage clinical development. ORPHELIA Pharma has also solidified regional agreements in the European Union, the USA, and China while engaging in research projects through academic and industrial partnerships. The venture round investment in ORPHELIA Pharma at 01 December 2017 was secured from Octalfa. This reflects growing confidence in the company's potential and the recognition of its crucial role in addressing unmet medical needs for children with rare diseases within the Life Sciences and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 | Octalfa | 01 Dec 2017 |
| Venture Round | Unknown | 1 | Octalfa | 09 Oct 2015 |
No recent news or press coverage available for ORPHELIA Pharma.
We care about your data, and we'd love to use cookies make your experience better.
